Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis
- 1 July 2006
- journal article
- Published by American Society of Hematology in Blood
- Vol. 108 (1) , 403-404
- https://doi.org/10.1182/blood-2006-01-0154
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2006
- Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myelomaBlood, 2005
- The Role of Aspirin in the Prevention of Thrombotic Complications of Thalidomide and Anthracycline-Based Chemotherapy for Multiple MyelomaMayo Clinic Proceedings, 2005
- Study of Lenalidomide Plus Dexamethasone Versus Dexamethasone Alone in Relapsed or Refractory Multiple Myeloma (MM): Results of a Phase 3 Study (MM-010).Blood, 2005
- Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulationBritish Journal of Haematology, 2004
- Thalidomide Alone or With Dexamethasone for Previously Untreated Multiple MyelomaJournal of Clinical Oncology, 2003
- Combination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed MyelomaJournal of Clinical Oncology, 2002